文献速递白血病

多基因Ara-C反应评分识别需要化疗强化的儿童急性髓系白血病患者

Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
PubMed 文献 · J Clin Oncol · 2022-01-06

研究基于阿糖胞苷(ara-C)通路药物基因组学建立患者特异性多基因评分,以个体化急性髓系白血病(AML)治疗。利用多中心AML02试验(N=166)中与微小残留病和无事件生存(EFS)相关的顶级SNP及AML97试验中4个与ara-C三磷酸水平相关的SNP,构建10-SNP评分(ACS10),并在AML02标准低剂量ara-C组(n=91)与强化高剂量ara-C组(n=75)、AAML0531标准ADE组(n=465)与强化ADE+吉妥珠单抗奥唑米星(GO)组(n=466)中评估其与结局的关联。

要点

  • 在标准低剂量ara-C组中,低ACS10评分(≤0)组较高ACS10评分(>0)组EFS更差(HR=2.81,95%CI 1.45-5.43,P=.002)。
  • 低ACS10评分组在标准方案治疗时结局显著较差,而强化治疗(高剂量ara-C或加用GO)可改善其结局。
  • ACS10评分可识别具有不利药物遗传学特征的患者,为选择性强化治疗提供潜在选项。

核心结论

  • 低ACS10评分患者在接受标准方案治疗时结局显著较差。
  • 采用高剂量ara-C或加用GO的强化治疗可改善低ACS10评分组的结局。
  • 多基因ACS10评分可识别具有不利药物遗传学特征的患者,为选择性强化治疗提供潜在选项。

研究设计与样本

  • 基于多中心AML02试验(N=166)中ara-C通路基因的SNP与结局分析,利用多SNP预测模型构建10-SNP ACS10评分。
  • ACS10评分在AML02试验的标准低剂量ara-C组(n=91)和强化高剂量ara-C组(n=75)中评估。
  • ACS10评分在AAML0531试验的标准ADE组(n=465)和强化ADE+GO组(n=466)中评估。

主要发现

  • 在AML02标准低剂量ara-C组中,低ACS10评分(≤0)组较高ACS10评分(>0)组EFS显著更差(HR=2.81,95%CI 1.45-5.43,P=.002),OS亦显著更差(HR=2.98,95%CI 1.32-6.75,P=.009)。
  • 在AAML0531标准ADE组中验证,低ACS10评分组较高ACS10评分组EFS更差(HR=1.35,95%CI 1.04-1.75,P=.026),OS更差(HR=1.64,95%CI 1.2-2.22,P=.002)。
  • 在强化治疗组(AML02-HDAC和AAML0531-ADE+GO)中,低与高ACS10评分组之间的EFS和OS无显著差异。
  • 在两个队列中,低ACS10评分患者接受强化治疗(AML02-HDAC或AAML0531-ADE+GO组)较标准治疗(AML02-LDAC或AAML0531-ADE组)的5年EFS一致改善10个百分点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To establish a patient-specific polygenic score derived from cytarabine (ara-C) pathway pharmacogenomic evaluation to personalize acute myeloid leukemia (AML) treatment. MATERIALS AND METHODS: Single nucleotide polymorphisms (SNPs) in the ara-C-pathway genes were analyzed with outcome in patients from the multicenter-AML02 trial (N = 166). Multi-SNP predictor modeling was used to develop 10-SNP Ara-C_SNP score (ACS10) using top SNPs predictive of minimal residual disease and event-free survival (EFS) from the AML02-cohort and four SNPs previously associated with ara-C triphosphate levels in the AML97 trial. ACS10 was evaluated for association with outcomes in each clinical trial arms: the standard low-dose ara-C (LDAC, n = 91) and augmented high-dose ara-C (HDAC, n = 75) arms of AML02 and the standard Ara-C, daunorubicin and etoposide (ADE) (n = 465) and the augmented ADE + gemtuzumab ozogamicin (GO; n = 466) arms of AAML0531 trial. RESULTS: In the standard LDAC-arm of AML02 cohort, the low-ACS10 score group (≤ 0) had significantly worse EFS (ACS10 low v high hazard ratio [HR] = 2.81; 95% CI, 1.45 to 5.43; P = .002) and overall survival (OS; HR = 2.98; 95% CI, 1.32 to 6.75; P = .009) compared with the high-ACS10 group (score > 0). These results were validated in the standard-ADE arm of AAML0531, with poor outcome in the low-ASC10 group compared with the high-ACS10 group (EFS: HR = 1.35, 95% CI, 1.04 to 1.75, P = .026; OS: HR = 1.64, 95% CI, 1.2 to 2.22, P = .002). Within the augmented arms (AML02-HDAC and AAML0531-ADE + GO), EFS and OS did not differ between low- and high-ACS10 score groups. In both cohorts, patients with low-ACS10 consistently showed a 10-percentage point improvement in 5-year EFS with augmented therapy (AML02-HDAC or AAML0531-ADE + GO arms) than with standard therapy (AML02-LDAC or AAML0531-ADE arms). CONCLUSION: Patients with low-ACS10 score experienced significantly poor outcome when treated on standard regimen. Augmentation with either high-dose ara-C or GO addition improved outcome in low-ACS10 group. A polygenic ACS10 score can identify patients with unfavorable pharmacogenetic characteristics and offers a potential for an elective augmented therapy option.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Elsayed AH, Cao X, Mitra AK, et al. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. J Clin Oncol. 2022. PMID: 34990262. doi:10.1200/JCO.21.01422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。